Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.11 CHF 0.71% Market Closed
Market Cap: 141.9m CHF

Profitability Summary

Newron Pharmaceuticals SpA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Newron Pharmaceuticals SpA

Revenue
51.4m EUR
Cost of Revenue
-892k EUR
Gross Profit
50.5m EUR
Operating Expenses
-24.3m EUR
Operating Income
26.2m EUR
Other Expenses
-10.3m EUR
Net Income
15.8m EUR

Margins Comparison
Newron Pharmaceuticals SpA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
IT
Newron Pharmaceuticals SpA
SIX:NWRN
141.9m CHF
98%
51%
31%
US
Eli Lilly and Co
NYSE:LLY
722.9B USD
82%
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
360.3B USD
68%
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
84%
45%
35%
CH
Roche Holding AG
SIX:ROG
206.2B CHF
74%
33%
14%
CH
Novartis AG
SIX:NOVN
185.9B CHF
76%
33%
24%
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP
82%
24%
14%
US
Merck & Co Inc
NYSE:MRK
198.9B USD
78%
34%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
136.3B USD
75%
27%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Newron Pharmaceuticals SpA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IT
Newron Pharmaceuticals SpA
SIX:NWRN
141.9m CHF
-111%
35%
140%
62%
US
Eli Lilly and Co
NYSE:LLY
722.9B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
360.3B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
206.2B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
185.9B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
198.9B USD
39%
16%
25%
19%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
136.3B USD
9%
4%
10%
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less